Kenji Mitsugi

4.2k total citations
59 papers, 664 citations indexed

About

Kenji Mitsugi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kenji Mitsugi has authored 59 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Kenji Mitsugi's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Gastric Cancer Management and Outcomes (12 papers). Kenji Mitsugi is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and Gastric Cancer Management and Outcomes (12 papers). Kenji Mitsugi collaborates with scholars based in Japan, United States and Greece. Kenji Mitsugi's co-authors include Hiroshi Ariyama, Eishi Baba, Shuji Nakano, Risa Tanaka, Taito Esaki, Hitoshi Kusaba, Koichi Akashi, Mine Harada, Yoshiyuki Niho and Yoshihiro Shibata and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kenji Mitsugi

56 papers receiving 662 citations

Peers

Countries citing papers authored by Kenji Mitsugi

Since Specialization

Citations

This map shows the geographic impact of Kenji Mitsugi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Mitsugi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Mitsugi more than expected).

Fields of papers citing papers by Kenji Mitsugi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Mitsugi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Mitsugi. The network helps show where Kenji Mitsugi may publish in the future.

Co-authorship network of co-authors of Kenji Mitsugi

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Mitsugi. A scholar is included among the top collaborators of Kenji Mitsugi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Mitsugi. Kenji Mitsugi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study 2023 ·International Journal of Clinical Oncology ·Azusa Komori, Satoshi Otsu, Mototsugu Shimokawa, Taiga Otsuka, (unknown), (unknown), (unknown), Shiho Arima, Masaru Fukahori, Yoshinobu Okabe, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Kenta Nio, Yasushi Ide, (unknown), Toshihiko Mizuta, Tsuyoshi Shirakawa, Kenji Mitsugi	1
2	MO61-6 Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer 2023 ·Annals of Oncology ·(unknown), Tsuyoshi Shirakawa, Mototsugu Shimokawa, Taiga Otsuka, (unknown), Taro Shibuki, (unknown), Shiho Arima, Keisuke Miwa, (unknown), (unknown), (unknown), (unknown), (unknown), Azusa Komori, Ayumu Hosokawa, Tatsunori Sakai, (unknown), Toshihiko Mizuta, Kenji Mitsugi	0
3	A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site 2022 ·Japanese Journal of Clinical Oncology ·Kazuo Nishikawa, Shuichi Hironaka, Takashi Inagaki, Azusa Komori, Satoshi Otsu, Kenji Mitsugi, (unknown), (unknown), Shingo Tamura, Yuta Okumura, Hitoshi Kusaba, (unknown), Eishi Baba, Kuniaki Shirao	2
4	Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study) 2022 ·BMC Cancer ·Taro Shibuki, Toshihiko Mizuta, Mototsugu Shimokawa, (unknown), (unknown), (unknown), Azusa Komori, Satoshi Otsu, Shiho Arima, Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Kenji Mitsugi, Kenta Nio, Yasushi Ide, (unknown), Tsuyoshi Shirakawa, Taiga Otsuka	7
5	OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody 2020 ·British Journal of Cancer ·Hirofumi Ohmura, Toshihiro Yamaguchi, (unknown), Mamoru Ito, Akitaka Makiyama, Keita Uchino, (unknown), Shingo Tamura, Taito Esaki, Kenji Mitsugi, Yoshihiro Shibata, Hisanobu Oda, Kenji Tsuchihashi, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba	51
6	PD-5 Impact of biliary drainage for unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel: Results from the NAPOLEON study 2020 ·Annals of Oncology ·T Honda, (unknown), Mototsugu Shimokawa, (unknown), (unknown), (unknown), (unknown), (unknown), Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Taro Shibuki, Kenta Nio, Yasushi Ide, (unknown), Kenji Mitsugi, Taiga Otsuka, Tsuyoshi Shirakawa	0
7	A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study 2019 ·Annals of Oncology ·(unknown), Taiga Otsuka, Mototsugu Shimokawa, (unknown), (unknown), Satoshi Otsu, (unknown), Masaru Fukahori, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Taro Shibuki, Tsuyoshi Shirakawa, Kenji Mitsugi, Kenta Nio, Yasushi Ide, (unknown)	5
8	The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Toshihiro Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, Kenji Mitsugi, Keita Uchino, Shingo Tamura, Yoshihiro Shibata, Taito Esaki, Mamoru Ito, (unknown), Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba	12
9	Analysis of a Questionnaire Survey regarding Current Conditions against Exposure to Anticancer Drugs and Reports of Cancer Chemotherapy at Outpatient Departments in Japan 2017 ·Pharmacology &amp Pharmacy ·Tsuyoshi Shirakawa, (unknown), Kojiro Hata, Kimitaka Suetsugu, (unknown), Kentaro Ogata, (unknown), (unknown), Makoto Takahashi, Masaru Fukahori, (unknown), Taito Esaki, (unknown), Toshinobu Hayashi, Akira Tokunaga, (unknown), (unknown), Hitoshi Kusaba, Kenji Mitsugi, Eishi Baba	0
10	Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer 2017 ·Cancer Chemotherapy and Pharmacology ·(unknown), Hitoshi Kusaba, (unknown), Kenji Mitsugi, (unknown), Akitaka Makiyama, Keita Uchino, Tsuyoshi Shirakawa, Yoshihiro Shibata, (unknown), (unknown), Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Taito Esaki, Koichi Akashi, Eishi Baba	16
11	Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy 2015 ·Cancer Chemotherapy and Pharmacology ·Kenta Nio, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenichi Kohashi, (unknown), Shingo Tamura, Gen Hirano, Kenji Mitsugi, Akitaka Makiyama, Taito Esaki, Hiroshi Ariyama, Yoshinao Oda, Koichi Akashi, Eishi Baba	14
12	Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer 2012 ·Cancer Chemotherapy and Pharmacology ·Hitoshi Kusaba, Taito Esaki, Junji Kishimoto, Keita Uchino, Shuji Arita, (unknown), Kenji Mitsugi, Koichi Akashi, Eishi Baba	1
13	Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer 2010 ·Cancer Chemotherapy and Pharmacology ·Eishi Baba, Taito Esaki, Hiroshi Ariyama, Kenji Mitsugi, (unknown), (unknown), Hitoshi Kusaba, Shuji Nakano, Koichi Akashi	1
14	Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma 2010 ·Oncology Letters ·Yoshihiro Shibata, Eishi Baba, Hiroshi Ariyama, Shuji Arita, Taichi Isobe, Hitoshi Kusaba, Kenji Mitsugi, Shuji Nakano, Koichi Akashi	1
15	Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan 2009 ·International Journal of Clinical Oncology ·Yoshihiro Shibata, Hiroshi Ariyama, Eishi Baba, Yasushi Takii, Taito Esaki, Kenji Mitsugi, (unknown), Hitoshi Kusaba, Koichi Akashi, Shuji Nakano	31
16	Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site 2007 ·Medical Oncology ·Hitoshi Kusaba, Yoshihiro Shibata, Shuji Arita, Hiroshi Ariyama, Eishi Baba, Kenji Mitsugi, Mine Harada, Shuji Nakano	2
17	Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer 2005 ·Cancer Chemotherapy and Pharmacology ·(unknown), Ken Kato, Kenji Mitsugi, Minoru Nakamura, Risa Tanaka, Eishi Baba, Hiroshi Ariyama, Toshiro Kuroiwa, Mine Harada, Shuji Nakano	3
18	In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines 2005 ·Cancer Chemotherapy and Pharmacology ·Risa Tanaka, Yasushi Takii, Yoshihiro Shibata, Hiroshi Ariyama, (unknown), Eishi Baba, Hitoshi Kusaba, Kenji Mitsugi, Mine Harada, Shuji Nakano	9
19	Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells 2005 ·Journal of Cellular Biochemistry ·Hiroshi Ariyama, (unknown), Eishi Baba, Risa Tanaka, Kenji Mitsugi, Mine Harada, Shuji Nakano	59
20	Organization and Alternate Splicing of the Murine Folylpolyglutamate Synthetase Gene 1996 ·Journal of Biological Chemistry ·Krishnendu Roy, Kenji Mitsugi, Francis M. Sirotnak	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact